Arovella Therapeutics Limited (ALA.AX)
AUD 0.18
(5.88%)
AUD 0.18
(5.88%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 17 Thousand | 405.89 Thousand | 295.81 Thousand | 257.34 Thousand | 532.69 Thousand | 1.21 Million |
| Cost of Revenue | 42.97 Thousand | 3.4 Million | 207.05 Thousand | 222.75 Thousand | 200.96 Thousand | 199.68 Thousand |
| Gross Profit | -25.97 Thousand | -2.99 Million | 88.75 Thousand | 34.59 Thousand | 331.72 Thousand | 1.01 Million |
| Operating Expenses | 10.78 Million | 6.68 Million | 7.68 Million | 4.7 Million | 5.13 Million | 3.4 Million |
| Selling, General and Administrative Expenses | 2.77 Million | 2.69 Million | 2.79 Million | 2.16 Million | 2.17 Million | 1.18 Million |
| Research and Development Expenses | 6.73 Million | 3.98 Million | 2.59 Million | 541.55 Thousand | 228.77 Thousand | 6.68 Million |
| Other Expenses | - | 1.04 Million | - | 906.67 Thousand | 798.73 Thousand | 31.69 Thousand |
| Cost and Expenses | 10.82 Million | 10.08 Million | 7.89 Million | 4.92 Million | 5.33 Million | 3.59 Million |
| Operating Income | -7.19 Million | -9.68 Million | -7.59 Million | -3.75 Million | -3.97 Million | -2.31 Million |
| Interest Expense | 8631.00 | 20.67 Thousand | 194.72 Thousand | 33.29 Thousand | 6570.00 | 125.06 Thousand |
| Income Tax Expense | - | -1.04 Million | 194.72 Thousand | 939.96 Thousand | 805.3 Thousand | -925 Thousand |
| Earnings before Tax | -8.74 Million | -11.23 Million | -8.62 Million | -5.04 Million | -9.94 Million | -8.72 Million |
| Net Income | -8.74 Million | -10.18 Million | -8.62 Million | -5.04 Million | -9.94 Million | -7.79 Million |
| Earnings Per Share Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.06 | -0.07 |
| Earnings Per Share Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.06 | -0.07 |
| Weighted Average Shares Outstanding | 941.42 Million | 711.48 Million | 549.62 Million | 330.89 Million | 167.9 Million | 116.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 941.42 Million | 711.48 Million | 549.62 Million | 330.89 Million | 167.9 Million | 116.35 Million |
| Gross Margin | -1.53 | -7.39 | 0.30 | 0.13 | 0.62 | 0.84 |
| EBIT Margin | -519.60 | -21.79 | -23.80 | -12.05 | -6.39 | -1.52 |
| Profit Margin | -514.47 | -25.08 | -29.14 | -19.61 | -18.67 | -6.39 |
| EBITDA | -8.83 Million | -10.37 Million | -7.87 Million | -4.99 Million | -3.4 Million | -8.12 Million |
| Earnings Before Tax Margin | -423.12 | -23.85 | -25.67 | -14.58 | -7.46 | -1.90 |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 4250.00 | 17 Thousand | 4250.00 | 8500.00 | 971.81 Thousand | 26.31 Thousand |
| Cost of Revenue | 20.16 Thousand | 42.97 Thousand | - | 1.47 Million | - | 1.49 Million |
| Gross Profit | -15.91 Thousand | -25.97 Thousand | 4250.00 | -1.46 Million | 971.81 Thousand | -1.47 Million |
| Operating Expenses | 2.01 Million | 10.78 Million | 2.01 Million | 4.49 Million | 2.98 Million | 3.28 Million |
| Selling, General and Administrative Expenses | 480.2 Thousand | - | 480.2 Thousand | 835.58 Thousand | 724.72 Thousand | 962.93 Thousand |
| Research and Development Expenses | 1.53 Million | - | 1.53 Million | 3.65 Million | 1.82 Million | 2.32 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 2.01 Million | 10.82 Million | 2.01 Million | 5.96 Million | 2.98 Million | 4.78 Million |
| Operating Income | -2.01 Million | -10.81 Million | -2.01 Million | -5.95 Million | -2.01 Million | -4.75 Million |
| Interest Expense | - | 8631.00 | - | - | - | - |
| Income Tax Expense | -2.00 | -1.93 Million | -412.34 Thousand | -1.93 Million | - | -1.00 |
| Earnings before Tax | -2.4 Million | -10.68 Million | -2.4 Million | -5.88 Million | -1.97 Million | -6.28 Million |
| Net Income | -2.4 Million | -8.74 Million | -2.4 Million | -3.94 Million | -1.97 Million | -6.28 Million |
| Earnings Per Share Basic | -0.00 | - | -0.00 | -0.00 | -0.00 | -0.01 |
| Earnings Per Share Diluted | -0.00 | - | -0.00 | -0.00 | -0.00 | -0.01 |
| Weighted Average Shares Outstanding | 982.45 Million | 941.42 Million | 982.45 Million | 900.51 Million | 896.76 Million | 739.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 982.33 Million | 941.42 Million | 982.33 Million | 900.51 Million | 900.51 Million | 739.32 Million |
| Gross Margin | -3.74 | -1.53 | 1.00 | -172.21 | 1.00 | -55.89 |
| EBIT Margin | -568.55 | - | -568.55 | -698.31 | -2.06 | -176.47 |
| Profit Margin | -564.74 | -514.47 | -564.74 | -464.21 | -2.03 | -238.78 |
| EBITDA | -2.41 Million | - | -2.41 Million | -5.93 Million | -2 Million | -4.64 Million |
| Earnings Before Tax Margin | -473.89 | -635.96 | -473.89 | -701.00 | -2.07 | -180.73 |
KEC
PEGA
7067
600758
IGM
NAUKRI